ACER

Stats

Summary

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); emetine hydrochloride, a host-directed therapy against a variety of infectious diseases, initially for the treatment of patients with COVID-19; EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer's product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.

Market Cap: 18.7 Million

Primary Exchange: NASDAQ

Website: acertx.com

Shares Outstanding: 15.3 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.76052997047504

Sector:

Industry:

Ethical Flags

Longest drawdown: 2560 trading days

From: 2013-02-05 To: 2022-06-24

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor
2017-09-21				10.355527	1.0	10.355527
2015-09-29				8.0	1.0	8.0